

State of the Union: Current asthma morbidity in the UK

First published: 10/03/2015

Last updated: 26/08/2015

Study

Finalised

Administrative details

EU PAS number

EUPAS8740

Study ID

10780

DARWIN EU® study

No

Study countries

☐ United Kingdom

Study description

Asthma is a chronic condition with significant health and economic consequences, which may be attributable to poor control. This study characterises patients with asthma from 153 UK primary care practices and

evaluates their disease severity, control and treatment.

Study status

Finalised

Research institutions and networks

Institutions

Research in Real Life

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Networks

Respiratory Effectiveness Group (REG)

- ☐ Belgium
- ☐ Denmark
- ☐ France
- ☐ Germany
- ☐ Greece
- ☐ Hungary
- ☐ Italy
- ☐ Netherlands
- ☐ Spain

☐ Sweden

☐ United Kingdom

First published: 07/07/2021

Last updated: 04/06/2024

Network

ENCePP partner

Contact details

Study institution contact

David Price david@rirl.org

Study contact

david@rirl.org

Primary lead investigator

Arjun Jain

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/04/2014

Actual: 01/04/2014

Study start date

Planned: 15/04/2014

Actual: 15/04/2014

Date of final study report

Planned: 12/08/2015

Actual: 31/07/2015

Sources of funding

- Pharmaceutical company and other private sector
- Other

More details on funding

Teva, Respiratory Effectiveness Group

Regulatory

Was the study required by a regulatory body?

No

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Other

Study topic, other:

Disease/Epidemiology study

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Data collection methods:

Secondary use of data

Main study objective:

This study will characterise patients with asthma from UK primary care practices and evaluates their disease severity, control and treatment.

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Medical condition to be studied

Asthma

Population studied

Short description of the study population

Clinician-diagnosed asthma patients (i.e. a diagnostic Read code for asthma compatible with UK Quality and Outcomes Framework) who have been receiving current asthma therapy (≥ 1 asthma prescription in the last 2 years)

Age groups

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Asthma patients

Estimated number of subjects

30000

Study design details

Data analysis plan

Pooled practice and patient data will be used to characterise patients in terms of control status (classified by the Global INitiative for Asthma GINA and Royal College of Physician three questions), risk status (according to severe exacerbation frequency, defined as the number of asthma related

hospitalisations and courses of acute oral steroids in previous 12 months), treatment step (as classified by GINA), and smoking status (current, ex-smoker or non-smoker). Summary statistics will be produced for all variables: for those measured on the interval/ratio scale, n and % of non-missing data, mean (standard deviation) or median (inter-quartile range), for categorical variables, n (%) of non-missing data and n (%) per category.

Data management

Data sources

Data source(s), other

Optimum Patient Care Research Database (OPCRD) United Kingdom

Data sources (types)

[Electronic healthcare records \(EHR\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No